Suppr超能文献

CDK 抑制剂在阿尔茨海默病中的药理作用。

Pharmacological relevance of CDK inhibitors in Alzheimer's disease.

机构信息

Molecular Neuroscience and Functional Genomics Laboratory, Delhi Technological University (Formerly Delhi College of Engineering), India.

Molecular Neuroscience and Functional Genomics Laboratory, Delhi Technological University (Formerly Delhi College of Engineering), India.

出版信息

Neurochem Int. 2021 Sep;148:105115. doi: 10.1016/j.neuint.2021.105115. Epub 2021 Jun 25.

Abstract

Evidence suggests that cell cycle activation plays a role in the pathophysiology of neurodegenerative diseases. Alzheimer's disease is a progressive, terminal neurodegenerative disease that affects memory and other important mental functions. Intracellular deposition of Tau protein, a hyperphosphorylated form of a microtubule-associated protein, and extracellular aggregation of Amyloid β protein, which manifests as neurofibrillary tangles (NFT) and senile plaques, respectively, characterize this condition. In recent years, however, several studies have concluded that cell cycle re-entry is one of the key causes of neuronal death in the pathogenesis of Alzheimer's disease. The eukaryotic cell cycle is well-coordinated machinery that performs critical functions in cell replenishment, such as DNA replication, cell creation, repair, and the birth of new daughter cells from the mother cell. The complex interplay between the levels of various cyclins and cyclin-dependent kinases (CDKs) at different checkpoints is needed for cell cycle synchronization. CDKIs (cyclin-dependent kinase inhibitors) prevent cyclin degradation and CDK inactivation. Different external and internal factors regulate them differently, and they have different tissue expression and developmental functions. The checkpoints ensure that the previous step is completed correctly before starting the new cell cycle phase, and they protect against the transfer of defects to the daughter cells. Due to the development of more selective and potent ATP-competitive CDK inhibitors, CDK inhibitors appear to be on the verge of having a clinical impact. This avenue is likely to yield new and effective medicines for the treatment of cancer and other neurodegenerative diseases. These new methods for recognizing CDK inhibitors may be used to create non-ATP-competitive agents that target CDK4, CDK5, and other CDKs that have been recognized as important therapeutic targets in Alzheimer's disease treatment.

摘要

有证据表明,细胞周期激活在神经退行性疾病的病理生理学中起作用。阿尔茨海默病是一种进行性、终末期的神经退行性疾病,影响记忆和其他重要的精神功能。细胞内 Tau 蛋白的沉积,Tau 蛋白是微管相关蛋白的一种高度磷酸化形式,以及细胞外淀粉样 β 蛋白的聚集,分别表现为神经原纤维缠结(NFT)和老年斑,是这种情况的特征。然而,近年来,几项研究得出结论,细胞周期再进入是阿尔茨海默病发病机制中神经元死亡的关键原因之一。真核细胞周期是一种协调良好的机制,在细胞补充中发挥着关键作用,例如 DNA 复制、细胞生成、修复以及从母细胞产生新的子细胞。不同检查点的各种细胞周期蛋白和细胞周期蛋白依赖性激酶(CDK)的水平之间的复杂相互作用是细胞周期同步所必需的。CDKI(细胞周期蛋白依赖性激酶抑制剂)可防止细胞周期蛋白降解和 CDK 失活。不同的外部和内部因素对它们进行不同的调节,它们具有不同的组织表达和发育功能。检查点确保在上一个细胞周期阶段开始之前正确完成上一个步骤,并防止缺陷传递到子细胞。由于更具选择性和更有效的 ATP 竞争性 CDK 抑制剂的发展,CDKI 似乎即将产生临床影响。这条途径很可能为癌症和其他神经退行性疾病的治疗带来新的、有效的药物。这些识别 CDK 抑制剂的新方法可用于创建非 ATP 竞争性药物,这些药物可靶向 CDK4、CDK5 和其他 CDKs,这些 CDKs 已被认为是阿尔茨海默病治疗的重要治疗靶点。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验